Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024)

Contineum Therapeutics (CTNM) has 1 years of Accumulated Depreciation data on record, last reported at $1.7 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation changed N/A year-over-year to $1.7 million; the TTM value through Dec 2024 reached $1.7 million, changed N/A, while the annual FY2024 figure was $1.7 million, N/A changed from the prior year.
  • Accumulated Depreciation reached $1.7 million in Q4 2024 per CTNM's latest filing.
  • Across five years, Accumulated Depreciation topped out at $1.7 million in Q4 2024 and bottomed at $1.7 million in Q4 2024.